Drugs / cMet RNA CAR T cells
cMet RNA CAR T cells
also known as
mRNA-transfected c-Met-CAR T cells
Cell therapy targets MET via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01837602 | Apr 2013 → Aug 2018 | triple-negative breast carcinoma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cMet RNA CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01837602 ↗ |
| Known as | mRNA-transfected c-Met-CAR T cells | “We then evaluated the safety and feasibility of treating metastatic breast cancer with intratumoral administration of mRNA-transfected c-Met-CAR T cells in a phase 0 clinical...” PMID 29109077 ↗ Nov 2017 |
| Action | Deplete | “Tumors treated with intratumoral injected mRNA c-Met-CAR T cells were excised and analyzed by immunohistochemistry, revealing extensive tumor necrosis at the injection site,...” PMID 29109077 ↗ Nov 2017 |
| Modality | Cell therapy | “mRNA-transfected c-Met-CAR T cells” PMID 29109077 ↗ Nov 2017 |
| Route | Other | “intratumoral administration” NCT01837602 ↗ |
| Target | MET | “We found that the cell-surface molecule c-Met was expressed in ∼50% of breast tumors, prompting the construction of a CAR T cell specific for c-Met” PMID 29109077 ↗ Nov 2017 |